<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02625662</url>
  </required_header>
  <id_info>
    <org_study_id>NL53213.091.15</org_study_id>
    <nct_id>NCT02625662</nct_id>
  </id_info>
  <brief_title>Facioscapulohumeral Dystrophy in Children</brief_title>
  <acronym>iFocus</acronym>
  <official_title>Facioscapulohumeral Dystrophy in Children: a Prospective, Observational Study on the Natural History, Predictors and Clinical Impact (iFocus)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Medical Center Nijmegen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Leiden University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Princess Beatrix Muscle Foundation</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University Medical Center Nijmegen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will focus on the symptoms, natural history and clinical impact of
      facioscapulohumeral muscular dystrophy (FSHD) in children.

      Symptoms of classical FSHD start in adulthood. However, a small subgroup of FSHD patients
      have an early, childhood onset. This early onset is associated with faster progression and
      other symptoms like hearing loss and epilepsy.

      The symptoms, natural history and clinical impact of FSHD in children are largely unknown.

      The results of this study will be vital for adequate symptomatic management and
      trial-readiness.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      FSHD is a hereditary muscle disease with slowly progressive muscle weakness. In children it
      is a very heterogenic disease ranging from severely affected infants to mildly affected
      adolescents. Symptoms can include muscle weakness, pain, fatigue, epilepsy, hearing loss,
      vision loss, mental retardation and spinal deformities. The prevalence of these symptoms and
      the adequate follow-up of these symptoms is unknown. Moreover the clinical impact and social
      functioning of children with FSHD is under exposed.

      Therefore this study will focus on the total spectrum of FSHD in children.

      In addition, an extensive genetic screening will be conducted, searching for (epi)genetic
      disease modifiers and severity predictors.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 2015</start_date>
  <completion_date type="Anticipated">September 2019</completion_date>
  <primary_completion_date type="Actual">August 2017</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Motor Function Measure</measure>
    <time_frame>2 years</time_frame>
    <description>Global motor functioning</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: Manual Muscle Testing</measure>
    <time_frame>2 years</time_frame>
    <description>Manual Muscle Testing using the 5-point scale of the Medical Research Council.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: 6 Minute Walk test</measure>
    <time_frame>2 years</time_frame>
    <description>Walking Distance in 6 minutes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: Denver II developmental screening test</measure>
    <time_frame>2 years</time_frame>
    <description>Developmental level.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: visual acuity</measure>
    <time_frame>2 years</time_frame>
    <description>Snellen card</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: hearing</measure>
    <time_frame>2 years</time_frame>
    <description>Tone- and voice audiometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: mental functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Electro-encephalography performed in clinically suspected epilepsy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: Pain</measure>
    <time_frame>2 years</time_frame>
    <description>Faces scale pain.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: cardiac functioning</measure>
    <time_frame>2 years</time_frame>
    <description>12 lead Electrocardiogram.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: respiratory functioning</measure>
    <time_frame>2 years</time_frame>
    <description>Upright sitting spirometry measuring vital capacity and forced expiratory volume.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: muscle functions</measure>
    <time_frame>2 years</time_frame>
    <description>FSHD-evaluation score, Ricci score.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body functioning: ingestion functions</measure>
    <time_frame>2 years</time_frame>
    <description>TOMASS-C test.Neuromuscular disease swallowing status scale.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body structure: muscle ultrasonography</measure>
    <time_frame>2 years</time_frame>
    <description>Quantitative muscle ultrasonography of 20 skeletal muscles.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICH Body structure: eye structure</measure>
    <time_frame>2 years</time_frame>
    <description>Dilated fundoscopy, optical coherence tomography, slit lamp examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICF: Activities and participation: Kidscreen</measure>
    <time_frame>2 years</time_frame>
    <description>Kidscreen-52.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICF: Activities and participation: NeuroQol</measure>
    <time_frame>2 years</time_frame>
    <description>NeuroQol fatigue domain, qualitative anamnesis.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICF: Activities and participation: SEV</measure>
    <time_frame>2 years</time_frame>
    <description>SEV questionnaire: social-emotional functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>(Epi)genetic disease-modifying factors</measure>
    <time_frame>2 years</time_frame>
    <description>Genetic profiling (DNA and RNA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalance estimation</measure>
    <time_frame>2 years</time_frame>
    <description>Nationwide recruitment, prevalence estimation.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Neurological Observations</condition>
  <condition>Facioscapulohumeral Muscular Dystrophy</condition>
  <condition>Pediatric Disorder</condition>
  <arm_group>
    <arm_group_label>iFSHD group</arm_group_label>
    <description>First recruitment group</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      DNA and RNA samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All children aged 0-17 years with genetically confirmed FSHD
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  aged 0-17 years

          -  symptoms of facial, scapulohumeral or peroneal weakness

          -  genetically proven FSHD1 or FSHD2

          -  living in the Netherlands

        Exclusion Criteria:

          -  no informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>17 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Baziel van Engelen, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Nijmegen University Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Radboud University Medical Center</name>
      <address>
        <city>Nijmegen</city>
        <state>Gelderland</state>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 2, 2015</study_first_submitted>
  <study_first_submitted_qc>December 4, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2015</study_first_posted>
  <last_update_submitted>October 31, 2017</last_update_submitted>
  <last_update_submitted_qc>October 31, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">November 1, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University Medical Center Nijmegen</investigator_affiliation>
    <investigator_full_name>RJM Goselink</investigator_full_name>
    <investigator_title>Prof. dr. Baziel van Engelen</investigator_title>
  </responsible_party>
  <keyword>muscular dystrophy</keyword>
  <keyword>natural history</keyword>
  <keyword>genetic profilling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Dystrophies</mesh_term>
    <mesh_term>Muscular Dystrophy, Facioscapulohumeral</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

